Tris DBA

N-myristoyltransferase-1 inhibitor; antiproliferative CAS# 51364-51-3

Tris DBA

Catalog No. BCC7685----Order now to get a substantial discount!

Product Name & Size Price Stock
Tris DBA: 5mg $69 In Stock
Tris DBA: 10mg Please Inquire In Stock
Tris DBA: 20mg Please Inquire Please Inquire
Tris DBA: 50mg Please Inquire Please Inquire
Tris DBA: 100mg Please Inquire Please Inquire
Tris DBA: 200mg Please Inquire Please Inquire
Tris DBA: 500mg Please Inquire Please Inquire
Tris DBA: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Tris DBA

Number of papers citing our products

Chemical structure

Tris DBA

3D structure

Chemical Properties of Tris DBA

Cas No. 51364-51-3 SDF Download SDF
PubChem ID 9811564 Appearance Powder
Formula C51H42O3Pd2 M.Wt 915.73
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 11 mM in DMSO
Chemical Name (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium
SMILES C1=CC=C(C=C1)C=CC(=O)C=CC2=CC=CC=C2.C1=CC=C(C=C1)C=CC(=O)C=CC2=CC=CC=C2.C1=CC=C(C=C1)C=CC(=O)C=CC2=CC=CC=C2.[Pd].[Pd]
Standard InChIKey CYPYTURSJDMMMP-WVCUSYJESA-N
Standard InChI InChI=1S/3C17H14O.2Pd/c3*18-17(13-11-15-7-3-1-4-8-15)14-12-16-9-5-2-6-10-16;;/h3*1-14H;;/b3*13-11+,14-12+;;
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Tris DBA

DescriptionN-myristoyltransferase-1 (NMT-1) inhibitor that prevents activation of MAPK, PI 3-K and STAT3 signaling pathways. Exhibits antiproliferative activity against melanoma cells in vitro and in vivo. Also used as a cyclization catalyst.

Tris DBA Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Tris DBA Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Tris DBA

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.092 mL 5.4601 mL 10.9202 mL 21.8405 mL 27.3006 mL
5 mM 0.2184 mL 1.092 mL 2.184 mL 4.3681 mL 5.4601 mL
10 mM 0.1092 mL 0.546 mL 1.092 mL 2.184 mL 2.7301 mL
50 mM 0.0218 mL 0.1092 mL 0.2184 mL 0.4368 mL 0.546 mL
100 mM 0.0109 mL 0.0546 mL 0.1092 mL 0.2184 mL 0.273 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Tris DBA

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.[Pubmed:26421357]

Leuk Lymphoma. 2016 Jul;57(7):1677-86.

Despite recent progress in novel and targeted therapies, multiple myeloma (MM) remains a therapeutically challenging incurable disease. The regulation of important cellular processes and its link to cancer presented Src as an attractive target for MM. We suggest a novel strategy to improve the treatment of MM and overcome the drug resistance for the current therapeutic agents by specific inhibition of Src in MM cells by Tris (Dibenzylideneacetone) dipalladium (Tris DBA). Tris DBA reduces proliferation, induces G1 arrest and apoptosis in MM cells. Tris DBA showed additive effect with proteasome inhibitors reducing proliferation, cell cycle signaling, and increasing apoptosis more than each drug alone. Tris DBA overcame hypoxia-induced effects such as enhanced chemotaxis or drug resistance to proteasome inhibitors by inhibition of HIF1alpha expression. Moreover, we found that Tris DBA is an effective anti-myeloma agent alone or in combination with other targeted drugs and that it reverses hypoxia-induced drug resistance in myeloma.

Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.[Pubmed:27438140]

Oncotarget. 2016 Aug 9;7(32):51569-51580.

Pancreatic carcinoma ranks among the most lethal of human cancers. Besides late detection, other factors contribute to its lethality, including a high degree of chemoresistance, invasion, and distant metastases. Currently, the mainstay of therapy involves resection of local disease in a minority of patients (Whipple procedure) and systemic gemcitabine. While systemic chemotherapy has some benefit, even with optimal treatment, the five year survival after diagnosis is dismal. Thus, treatment of pancreatic carcinoma remains a tremendous unmet need.The organometallic compound Tris DBA palladium is a potent inhibitor of N-myristoyltransferase 1 (NMT1), an enzyme that catalyzes the transfer of myristate to protein substrates. This compound is highly effective in vivo against murine models of melanoma with both mutant and wild type b-RAF genotypes. Based upon the signaling similarities between melanoma and pancreatic carcinoma, we evaluated the efficacy of Tris DBA palladium in vitro and in vivo against pancreatic carcinoma. We found that Tris DBA palladium decreased proliferation and colony formation of pancreatic cancer cells in vitro. In an orthotopic mouse model, Tris DBA palladium was highly active in inhibiting growth, ascites production, and distant metastases in vivo. Furthermore, Tris DBA palladium impaired chemotaxis and inhibited cilia formation in Pan02 cells in a NMT1-dependent manner. We propose that NMT1 is a novel regulator of cilia formation and Tris DBA palladium a novel inhibitor of cilia formation and metastasis in pancreatic cancer. Thus, further evaluation of Tris DBA palladium for the treatment of pancreatic cancer is warranted.

Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.[Pubmed:18794083]

Clin Cancer Res. 2008 Sep 15;14(18):5743-8.

PURPOSE: Melanoma is a solid tumor that is notoriously resistant to chemotherapy, and its incidence is rapidly increasing. Recently, several signaling pathways have been shown to contribute to melanoma tumorigenesis, including constitutive activation of mitogen-activated protein kinase, Akt, and Stat-3. The activation of multiple pathways may account in part for the difficulty in treatment of melanoma. In a recent screen of compounds, we found that an organopalladium compound, Tris (dibenzylideneacetone) dipalladium (Tris DBA), showed significant antiproliferative activity against melanoma cells. Studies were carried out to determine the mechanism of action of Tris DBA. EXPERIMENTAL DESIGN: Tris DBA was tested on efficacy on proliferation of human and murine melanoma cells. To find the mechanism of action of Tris DBA, we did Western blot and gene array analyses. The ability of Tris DBA to block tumor growth in vivo was assessed. RESULTS: Tris DBA has activity against B16 murine and A375 human melanoma in vivo. Tris DBA inhibits several signaling pathways including activation of mitogen-activated protein kinase, Akt, Stat-3, and S6 kinase activation, suggesting an upstream target. Tris DBA was found to be a potent inhibitor of N-myristoyltransferase-1, which is required for optimal activity of membrane-based signaling molecules. Tris DBA showed potent antitumor activity in vivo against melanoma. CONCLUSION: Tris DBA is thus a novel inhibitor of N-myristoyltransferase-1 with significant antitumor activity and is well tolerated in vivo. Further preclinical evaluation of Tris DBA and related complexes is warranted.

Keywords:

Tris DBA,51364-51-3,Natural Products,Transferase, buy Tris DBA , Tris DBA supplier , purchase Tris DBA , Tris DBA cost , Tris DBA manufacturer , order Tris DBA , high purity Tris DBA

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: